Larvol Delta - Apnimed-Announces-Dosing-of-First-Patient-in-Phase-2-MARIPOSA-Conrmatory-Trial-of-AD109-a-Potential-Nighttime-Oral-Treatment-for-Obstructive-Sleep-Apnea-OSA

aroxybutynin/atomoxetine (AD109) - Apnimed

https://www.businesswire.com/news/home/20211216005490/en/Arcturus-Therapeutics-Reports-New-Data-and-Provides-Additional-Updates-from-ARCT-154-and-ARCT-165-Clinical-Trials

Dec 16, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next